Glasses that 'Talk' to Gene-Edited eyes: a new hope for blindness?
NCT ID NCT03326336
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a combination treatment for retinitis pigmentosa, a genetic disease that causes blindness. Ten adults receive a single injection of GS030 gene therapy into one eye, then use special glasses that send light signals to the treated retina. The main goal is to check safety, but researchers also measure any changes in vision. The study is still ongoing and not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GS030 gene therapy (injected into the eye) plus special glasses that stimulate the treated retina with light
What this could lead to
If it works, this could restore some vision in people with retinitis pigmentosa who have lost most sight.
What could go wrong
This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The gene therapy and glasses are experimental, and vision improvement is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SYNDROMIC RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts
Paris, 75012, France
-
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
London, United Kingdom
-
UPMC Eye Center
Pittsburgh, Pennsylvania, 15213, United States